S. T. S. Durrant

740 total citations
25 papers, 381 citations indexed

About

S. T. S. Durrant is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, S. T. S. Durrant has authored 25 papers receiving a total of 381 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 11 papers in Oncology and 5 papers in Genetics. Recurrent topics in S. T. S. Durrant's work include Hematopoietic Stem Cell Transplantation (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Acute Myeloid Leukemia Research (3 papers). S. T. S. Durrant is often cited by papers focused on Hematopoietic Stem Cell Transplantation (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Acute Myeloid Leukemia Research (3 papers). S. T. S. Durrant collaborates with scholars based in United Kingdom, Australia and Germany. S. T. S. Durrant's co-authors include A. J. E. Flower, Claire Chapman, James Morton, Glen Kennedy, James H. Pringle, A Samanta, Geoffrey R. Hill, Jason Butler, Siok‐Keen Tey and I Lauder and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

S. T. S. Durrant

24 papers receiving 365 citations

Peers

S. T. S. Durrant
J Baró Spain
Antonella Di Mario Italy
Richard A. Savage United States
Laurence Clément France
Fábio R. Kerbauy Brazil
D I Marks United Kingdom
R Rokicka-Milewska Poland
R Brown United States
Norman Franke Canada
T Matsuyama Japan
J Baró Spain
S. T. S. Durrant
Citations per year, relative to S. T. S. Durrant S. T. S. Durrant (= 1×) peers J Baró

Countries citing papers authored by S. T. S. Durrant

Since Specialization
Citations

This map shows the geographic impact of S. T. S. Durrant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. T. S. Durrant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. T. S. Durrant more than expected).

Fields of papers citing papers by S. T. S. Durrant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. T. S. Durrant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. T. S. Durrant. The network helps show where S. T. S. Durrant may publish in the future.

Co-authorship network of co-authors of S. T. S. Durrant

This figure shows the co-authorship network connecting the top 25 collaborators of S. T. S. Durrant. A scholar is included among the top collaborators of S. T. S. Durrant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. T. S. Durrant. S. T. S. Durrant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tey, Siok‐Keen, Slavica Vučković, Antiopi Varelias, et al.. (2016). Pharmacokinetics and immunological outcomes of alemtuzumab-based treatment for steroid-refractory acute GvHD. Bone Marrow Transplantation. 51(8). 1153–1155. 3 indexed citations
2.
Delforge, Michel, Timothy Devos, Jacob M. Rowe, et al.. (2015). Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multi-center phase II trial. Leukemia & lymphoma. 57(2). 470–473. 2 indexed citations
3.
Durrant, S. T. S., Arnon Nagler, Alessandro M. Vannucchi, et al.. (2015). An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study. Blood. 126(23). 827–827. 18 indexed citations
4.
5.
Lancet, Jeffrey E., Andrew H. Wei, S. T. S. Durrant, et al.. (2013). A Phase I Study Of KB004, a Novel Non-Fucosylated humaneered® Antibody, Targeted Against The Receptor Tyrosine Kinase EphA3, In Advanced Hematologic Malignancies. Blood. 122(21). 3838–3838. 5 indexed citations
6.
Kennedy, Glen, Antiopi Varelias, Slavica Vučković, et al.. (2013). The Addition Of Interleukin-6 Inhibition To Standard Gvhd Prophylaxis Prevents Acute Gvhd: Interim Results Of a Phase I/II Clinical Study. Blood. 122(21). 908–908. 4 indexed citations
7.
Roberts, Andrew W., David Ritchie, Magnus Hertzberg, et al.. (2010). A phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML.. Journal of Clinical Oncology. 28(15_suppl). e13012–e13012. 21 indexed citations
8.
9.
Brouwer, Rolf E., Koos Zwinderman, W. R. Bezwoda, et al.. (1999). Phase III efficacy study of interleukin‐3 after autologous bone marrow transplantation in patients with malignant lymphoma. British Journal of Haematology. 106(3). 730–736. 2 indexed citations
10.
Morton, James, Darren P. Baker, Cheryl Hutchins, & S. T. S. Durrant. (1997). The COBE Spectra cell separator is more effective than the Haemonetics MCS‐3P cell separator for peripheral blood progenitor cell harvest after mobilization with cyclophosphamide and filgrastim. Transfusion. 37(6). 631–633. 17 indexed citations
11.
Durrant, S. T. S., J. Atherton, Thomas Moore, et al.. (1996). Demonstration of late cardiotoxicity following bone marrow transplantation by assessment of exercise diastolic filling characteristics.. PubMed. 17(6). 1113–8. 9 indexed citations
12.
Durrant, S. T. S., et al.. (1995). Efficacy of octreotide in controlling refractory diarrhea following bone marrow transplantation. Clinical Transplantation. 9(3pt1). 205–208. 12 indexed citations
13.
14.
Edmunds, M. E., Michael Devoy, Charles Tomson, et al.. (1991). Plasma erythropoietin levels and acquired cystic disease of the kidney in patients receiving regular haemodialysis treatment. British Journal of Haematology. 78(2). 275–277. 13 indexed citations
15.
Roffe, Christine, et al.. (1991). APLASTIC ANAEMIA IN SYSTEMIC LUPUS ERYTHEMATOSUS: A CELLULAR IMMUNE MECHANISM?. Lara D. Veeken. 30(4). 301–304. 28 indexed citations
16.
Chapman, Claire, A. J. E. Flower, & S. T. S. Durrant. (1991). The use of vidarabine in the treatment of human polyomavirus associated acute haemorrhagic cystitis.. PubMed. 7(6). 481–3. 40 indexed citations
17.
Hilton, David A., B P O'Malley, & S. T. S. Durrant. (1990). Histiocytic cytophagic panniculitis. Postgraduate Medical Journal. 66(781). 958–961. 7 indexed citations
18.
Akhtar, Naveed, et al.. (1989). In situ hybridization detection of light chain mRNA in routine bone marrow trephines from patients with suspected myeloma. British Journal of Haematology. 73(3). 296–301. 29 indexed citations
19.
Rahemtulla, Amin, et al.. (1986). Subacute encephalopathy associated with human immunodeficiency virus in haemophilia A.. BMJ. 293(6553). 993–993. 5 indexed citations
20.
Berthelsen, P. G., S. T. S. Durrant, Amin Rahemtulla, et al.. (1986). CENTRAL VENOUS CATHETERISATION. The Lancet. 328(8513). 974–975. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J Baró Breakdown of academic impact, for papers by Antonella Di Mario Breakdown of academic impact, for papers by Richard A. Savage Breakdown of academic impact, for papers by Laurence Clément Breakdown of academic impact, for papers by Fábio R. Kerbauy Breakdown of academic impact, for papers by D I Marks Breakdown of academic impact, for papers by R Rokicka-Milewska Breakdown of academic impact, for papers by R Brown Breakdown of academic impact, for papers by Norman Franke Breakdown of academic impact, for papers by T Matsuyama
Rankless by CCL
2026